THOMAS MASULLO: Open Payments
NPI 1821756057 · COLLINGSWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$419 in 25 payments from 9 companies in 2025. Trend: 2023 $37 · 2024 $429 · 2025 $419
Food & beverage: $419
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Vanda Pharmaceuticals Inc. | 3 | $52 |
| Tris Pharma Inc | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| E.R. Squibb & Sons, L.L.C. | 2 | $28 |
| Alkermes, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
Products named: VRAYLAR, REXULTI, CAPLYTA, FANAPT, Dyanavel XR, Auvelity, COBENFY, VIVITROL.
Industry payments across NJ — which companies pay providers there.
